268 related articles for article (PubMed ID: 32167970)
41. TGF-β1 signaling protects retinal ganglion cells from oxidative stress via modulation of the HO-1/Nrf2 pathway.
Chen HY; Ho YJ; Chou HC; Liao EC; Tsai YT; Wei YS; Lin LH; Lin MW; Wang YS; Ko ML; Chan HL
Chem Biol Interact; 2020 Nov; 331():109249. PubMed ID: 32980322
[TBL] [Abstract][Full Text] [Related]
42. Nrf2 antioxidant pathway suppresses Numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis.
Zhang Z; Qu J; Zheng C; Zhang P; Zhou W; Cui W; Mo X; Li L; Xu L; Gao J
Cell Death Dis; 2018 Jan; 9(2):83. PubMed ID: 29362432
[TBL] [Abstract][Full Text] [Related]
43. WNT/β-catenin signal inhibitor IC-2-derived small-molecule compounds suppress TGF-β1-induced fibrogenic response of renal epithelial cells by inhibiting SMAD2/3 signalling.
Hoi S; Tsuchiya H; Itaba N; Suzuki K; Oka H; Morimoto M; Takata T; Isomoto H; Shiota G
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):940-946. PubMed ID: 32012313
[TBL] [Abstract][Full Text] [Related]
44. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
45. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.
Luque AE; Cohn SE; Park JG; Cramer Y; Weinberg A; Livingston E; Klingman KL; Aweeka F; Watts DH
Antimicrob Agents Chemother; 2015 Apr; 59(4):2094-101. PubMed ID: 25624326
[TBL] [Abstract][Full Text] [Related]
46. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
47. Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.
Wilson ME; Sengoku T; Allred KF
J Cell Biochem; 2008 Apr; 103(5):1598-606. PubMed ID: 17879945
[TBL] [Abstract][Full Text] [Related]
48. AITC inhibits fibroblast-myofibroblast transition via TRPA1-independent MAPK and NRF2/HO-1 pathways and reverses corticosteroids insensitivity in human lung fibroblasts.
Yap JMG; Ueda T; Kanemitsu Y; Takeda N; Fukumitsu K; Fukuda S; Uemura T; Tajiri T; Ohkubo H; Maeno K; Ito Y; Oguri T; Ugawa S; Niimi A
Respir Res; 2021 Feb; 22(1):51. PubMed ID: 33579280
[TBL] [Abstract][Full Text] [Related]
49. Ureic clearance granule, alleviates renal dysfunction and tubulointerstitial fibrosis by promoting extracellular matrix degradation in renal failure rats, compared with enalapril.
Huang YR; Wei QX; Wan YG; Sun W; Mao ZM; Chen HL; Meng XJ; Shi XM; Tu Y; Zhu Q
J Ethnopharmacol; 2014 Sep; 155(3):1541-52. PubMed ID: 25087615
[TBL] [Abstract][Full Text] [Related]
50. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
51. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells.
Huang K; Chen C; Hao J; Huang J; Wang S; Liu P; Huang H
Mol Cell Endocrinol; 2015 Jan; 399():178-89. PubMed ID: 25192797
[TBL] [Abstract][Full Text] [Related]
52. The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro.
Loelius SG; Lannan KL; Blumberg N; Phipps RP; Spinelli SL
Thromb Res; 2018 Sep; 169():96-104. PubMed ID: 30031293
[TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
54. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
[TBL] [Abstract][Full Text] [Related]
55. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J; Conway B; Giguère P; Ferko N; Hollmann S; Angel JB
HIV Med; 2014 May; 15(5):301-10. PubMed ID: 24314017
[TBL] [Abstract][Full Text] [Related]
56. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
57. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
58. Low-dose paclitaxel ameliorates renal fibrosis by suppressing transforming growth factor-β1-induced plasminogen activator inhibitor-1 signaling.
Jung ES; Lee J; Heo NJ; Kim S; Kim DK; Joo KW; Han JS
Nephrology (Carlton); 2016 Jul; 21(7):574-82. PubMed ID: 26869361
[TBL] [Abstract][Full Text] [Related]
59. The soybean isoflavonoid equol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells.
Cheng C; Wang X; Weakley SM; Kougias P; Lin PH; Yao Q; Chen C
J Nutr; 2010 Jan; 140(1):12-7. PubMed ID: 19923382
[TBL] [Abstract][Full Text] [Related]
60. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group.
Nieuwkerk PT; Gisolf EH; Colebunders R; Wu AW; Danner SA; Sprangers MA
AIDS; 2000 Jan; 14(2):181-7. PubMed ID: 10708289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
